GlassScriptPhysician profile
Irving I Haber
NPI 1144227596
$28,599.70
in general payments reported to CMS, 2019-2025
52 companies · $1,679 in 2025
The $1,679 reported for 2025 was more than what 82% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $3,288 · 2021: $2,070 · 2022: $1,698 · 2023: $1,376 · 2024: $1,274 · 2025: $1,679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,127 · Education: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,126.98 |
| Education | $202.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $13,255.92 | 2019-2021 | |
| Kaleo, INC. | $5,529.25 | 2019 | |
| Radius Health, INC. | $1,371.63 | 2019-2025 | Tymlos |
| Collegium Pharmaceutical, INC. | $1,236.26 | 2019-2025 | Belbuca |
| Abbvie INC. | $1,116.33 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $692.96 | 2019-2023 | Relistor |
| Teva Pharmaceuticals USA, INC. | $603.26 | 2019-2025 | Austedo Xr, Austedo, Ajovy |
| Idorsia Pharmaceuticals US INC | $419.83 | 2022-2025 | Quviviq, Quviviq |
| Lilly USA, LLC | $344.80 | 2020-2025 | Kisunla, Emgality, Reyvow |
| Arbor Pharmaceuticals, INC. | $340.94 | 2019-2022 | |
| Amgen INC. | $335.92 | 2019-2023 | Aimovig |
| Eisai INC. | $320.48 | 2019-2022 | |
| Orexo US, INC. | $311.60 | 2019-2025 | Zubsolv |
| Scilex Pharmaceuticals INC. | $208.35 | 2019-2024 | Ztlido |
| Axsome Therapeutics, INC. | $200.27 | 2023-2025 | Sunosi, Symbravo |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irving Haber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.